GenomeScan Revenue and Competitors

Founded by research scientists and entrepreneurs in 2002, GenomeScan is a privately-owned company based in Leiden, The Netherlands. GenomeScan is a leading and innovative company in the field of genetic analyses. The company’s mission is to partner with hospitals, academic institutions, and global pharmaceutical and biotechnology companies to accelerate disease diagnostics and prediction, support clinician decision making, and improve the quality of life for patients suffering from genetic disorders. GenomeScan truly understands customers’ needs and develops tailored solutions. The company combines in-house expertise with a close collaboration with clinical experts from the prestigious Erasmus Medical Center and Leiden University Medical Center to develop an in-depth knowledge and understanding of a wide range of research methodologies and data-analysis and -interpretation relevant to clinical practice. In addition to providing patient stratification strategies based on NGS genetic profiling to pharmaceutical companies, GenomeScan’s services portfolio encompasses the latest sequencing technologies including whole exome sequencing, panel sequencing, transcriptomics, and epigenetics. GenomeScan maintains an accredited DNA testing facility (ISO/IEC 17025 accredited for NGS, also offering GCLP and GLP compliance for a variety of tests for large clinical and preclinical studies). The in-house laboratory is fully equipped to perform genetic tests for large clinical and drug development studies and deliver genetic profiles or diagnostics (including data interpretation) in 48 hours. Our industry-scale sequencers (NovaSeq 6000, PacBio Sequel), robotics and IT infrastructure have ample capacity to accommodate both research and diagnostics projects. An experienced bioinformatics team has developed pipelines for all our current services that can be customized to generate a comprehensive report tailored to your needs.